Lamivudine therapy for children with chronic hepatitis B

Table 2 Statistical analysis of factors predicting response to lamivudine treatment

Factors that may predict response	ALT normalisation	HBe/anti-HBeseroconversion	Sustained viralresponse
Sex	χ2(Y)=0.37, P = 0.54	χ2(Y)=0.13, P = 0.72	χ2(Y)=0.01, P = 0.76
Previous IFN-α treatment	χ2(Y)=0.70, P = 0.76.	χ2(Y)=3.29, P = 0.07	χ2(Y)=4.42, P = 0.04
Children’s age	Z=0.10, P = 0.92	Z=1.83, P = 0.07	Z=2.28, P = 0.02
Age of HBV infection	Z=0.70, P = 0.49	Z=-1.49, P = 0.14	Z=-1.40, P = 0.15
Duration of HBV infection	Z=0.13, P = 0.89	Z=2.99, P = 0.002	Z=3.33, P < 0.001
Inflammation activity score (grading)	Z=0.23, P = 0.82	Z=1.56, P = 0.12	Z=1.76, P = 0.08
Staging	Z=0.88, P = 0.38	Z=1.46, P = 0.14	Z=1.69, P = 0.09
ALT activity before treatment	Z=-0.48, P = 0.63	Z=1.49, P = 0.14	Z=1.23, P = 0.23
Serum HBV DNA level	Z=-0.80, P = 0.07	Z=-3.29, P = 0.001	Z=-3.22, P = 0.001
Lamivudnie dose per kg of body weight	Z=-0.46, P = 0.64	Z=-1.75, P = 0.08	Z=-1.59, P = 0.11